

Press Release Archives**January 09, 2003****Preference shares available for trading**

The preference shares of the following companies shall be listed and admitted to dealings on the Exchange w.e.f. January 13, 2003. Trading shall be in the Normal market segment (Rolling Settlement) for all investors.

Sr.No.	Name of the company	ISIN Code
1	Marico Industries Ltd.	INE196A04012
2	Sun Pharmaceutical Industries Ltd.	INE044A04014

[Top](#)**Press reports regarding M/s. Escorts Ltd.**

The press had reports on January 8, 2003, that Escorts Limited is offloading 20% shareholding in its healthcare business to overseas private equity investors.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Escorts Ltd. has vide its letter inter-alia stated, "We wish to inform you that the said news item is not an official press release issued by the Company".

[Top](#)**Press reports regarding M/s. Nicholas Piramal India Ltd.**

The press had reports on January 02, 2003 that Nicholas Piramal India Limited's new drug application was close to being approved by the Drug Controller General of India.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Nicholas Piramal India Limited has vide its letter inter-alia stated, "We would like to clarify that whilst the Company is committed to development of new drugs, which are in various stages of development, no new drug application has been recently filed with the Drug Controller General of India for approval."

[Top](#)**Press reports regarding M/s. Nicholas Piramal India Ltd.**

The press had reports on January 06, 2003 that:

i) Nicholas Piramal India Limited has announced recently the merger of Sumitra Pharma's bulk

drug plant with it. ii) The company is in the race to pick up a strategic stake in Hyderabad-based Shantha Biotechnics. iii) The company is in talks with the \$1.2 bn American drugmaker Ivax to market the latter's asthma inhalers in India.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Nicholas Piramal India Limited has vide its letter inter-alia stated, "We would like to clarify that: i) It is Global Bulk Drugs & Fine Chemicals Pvt. Ltd. which is being merged with the Company (and not Sumitra Pharmaceutical's bulk drug plant as erroneously reported). Global has a drug plant at Hyderabad which earlier belonged to Sumitra Pharmaceuticals & Chemicals Limited (SPCL). The bulk drug business of SPCL (including the aforesaid Plant) was transferred to NPIL with effect from 1st April 1995 pursuant to the Scheme of Arrangement sanctioned by the High Courts of Judicature of Andhra Pradesh at Hyderabad and of Bombay respectively. In 1988, NPIL had hived off this bulk drug business to Global as its wholly-owned subsidiary and subsequently, divested its equity shareholding in Global. Thus, whilst the said bulk drug plant once belonged to SPCL, it currently belongs to Global, which is being merged with NPIL. ii) There are no talks for acquiring a strategic stake in Shantha Biotechnics. iii) The news story regarding marketing of Ivax's asthma inhalers in India is speculative and inaccurate. The Company is associated with Ivax for research collaboration in certain areas."

[Top](#)

Press reports regarding M/s. Hexaware Technologies Ltd.

The press had reports on January 08, 2003 that Hexaware Technologies Limited is likely to bag an order for its BPO business.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Hexaware Technologies Limited has vide its letter inter-alia stated, "With reference to market grapevine, we would not like to comment on the same. As a part of routine business, the Company continues to pursue small, medium, as well as large opportunities including BPO business. During our quarterly result alongwith press release, we've already mentioned about new clients win during that respective quarter. We assure you that all the press release related to significant developments in the Company will be intimated to you in advance."

[Top](#)

Press reports regarding M/s. Glaxo Smitkline Pharmaceuticals Ltd.

The press had reports that Glaxo Smitkline Pharmaceuticals Limited is in the race for acquiring a stake in Lupin Limited.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Glaxo Smitkline Pharmaceuticals Limited has vide its letter inter-alia stated, "We would like to inform you that the news item is speculative in nature and hence, we are not in a position to comment on the same."

[Top](#)

Press reports regarding M/s. Hindustan Inks And Resins Ltd.

The press had reports that BASF AG, the \$32 billion German chemical giant is all set to acquire Hindustan Inks And Resins Limited from Bilakhias for about Rs 600 crore at Rs 440 per share.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Hindustan Inks And Resins Limited has vide its letter inter-alia stated, "We wish to clarify as follows: The Promoters of the Company deny any purchase of shares from the markets or involvement in any speculative activity and confirm that its shareholding has remained unchanged at 74.4% since end May, 2000. The Company does not have any reportable developments in accordance with the prevalent laws and regulations. Since the last three years the company has started focusing itself in the international markets and is now selling its products in more than 50 countries with the biggest presence in the US. In view of its international exposure and global ambitions, it is always exploring various types of strategic alliances in various countries, but denied having any agreement with any company."

[Top](#)

Press reports regarding M/s. State Bank of India

The press had reports on January 02, 2003 that the German regulator Bundesbank had slapped a fine for violating exposure norms on SBI's Frankfurt operations.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

State Bank of India has vide its letter inter-alia stated, "We advise that a notification was received by our Frankfurt Branch during August, 2001 from the Regulators alleging exceeding of a single borrower/group exposure limits as per local norms. In the proceeding which followed, the amount claimed by the Regulators was reduced by about eighty five percent since the alleged exceeding of exposure norms was purely technical in nature and beyond the control of the Bank. It was decided that there was no deliberate deviation of any Regulatory provisions by the Bank. In satisfaction of the matter, the amount has been paid and the matter stands fully resolved."

[Top](#)

Press reports regarding M/s. Shasun Chemicals & Drugs Ltd.

The press had reports that US based pharma major Eli Lilly and Company has signed a contract with Shasun Chemicals & Drugs Limited for contract manufacturing of methohexital and nizatidine for their global requirement.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Reply is awaited from Shasun Chemicals & Drugs Limited.

[Top](#)

Press reports regarding M/s. Pentasoft Technologies Ltd.

The press had reports that ACCPAC International which holds a 51% stake in ACCPAC India will acquire the balance 49% from its joint venture partner, Pentasoft Technologies.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Reply is awaited from Pentasoft Technologies Limited.

[Top](#)

Press reports regarding M/s. Dewan Housing Finance Corporation Ltd.

The press had reports that International Finance Corporation (IFC) is planning to invest Rs. 60 crore in Dewan Housing Finance Corporation Limited to fund its expansion plan.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Reply is awaited from Dewan Housing Finance Corporation Limited.

[Top](#)

Press reports regarding M/s. Bayer ABS Ltd.

The press had reports that there is an expectation of an open offer from Bayer Industries, holding 50.97% in Bayer ABS Limited. Further, the multinational would acquire the remaining floating stock from the shareholders and delist the stock.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Reply is awaited from Bayer ABS Limited.

[Top](#)

Press reports regarding M/s. Amtrex Hitachi Appliances Ltd.

The press had reports that Hitachi Home & Life Solutions Inc will pay Rs 41.2 per share to acquire the 19.4 per cent stake held by the Lalbhais in the AC manufacturing joint venture, Amtrex Hitachi Appliances Ltd. There were also reports that the company is mulling over possibility of putting up air-conditioner assembly facilities in Jammu.

The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.

Reply is awaited from Amtrex Hitachi Appliances Limited.

[Top](#)

The Exchange has successfully completed its 719th Normal Settlement

The Exchange has successfully completed its 719th Normal Settlement (Rolling T+3 following SEBI directive) since inception i.e., Settlement Number N - 2003004 on January 09, 2003. The settlement statistics are as follows:

Particulars	Values
	N - 2003004
Total traded quantity (lakhs)	1223.20
Total traded value (Rs. In Crores)	2395.57
Total value of the settlement (Securities) (Rs. In Crores)	359.80

Total value of the settlement (Funds) (Rs. In Crores)	114.82
Shortages for the settlement	0.38%
% of Delivery (No. of shares delivered / No. of shares traded)	23.19%

[Top](#)